Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 64,431,288
  • Shares Outstanding, K 201,480
  • Annual Sales, $ 3,529 M
  • Annual Income, $ -3,035,000 K
  • 36-Month Beta 0.95
  • Price/Sales 5.24
  • Price/Cash Flow 11.80
  • Price/Book 4.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/18
See More
  • Average Estimate 6.72
  • Number of Estimates 24
  • High Estimate 7.65
  • Low Estimate 5.96
  • Prior Year 5.26
  • Growth Rate Est. (year over year) +27.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
310.00 +4.07%
on 11/15/18
338.72 -4.76%
on 12/03/18
+3.71 (+1.16%)
since 11/12/18
3-Month
288.34 +11.89%
on 10/25/18
358.41 -9.99%
on 10/01/18
-17.42 (-5.12%)
since 09/12/18
52-Week
249.17 +29.47%
on 04/24/18
388.67 -17.00%
on 07/25/18
-5.14 (-1.57%)
since 12/12/17

Most Recent Stories

More News
Biotech Stock Roundup: Gilead to Get New CEO, Biogen In-Licenses Candidate

A low key week for the biotech sector with focus on regular pipeline updates.

CNAT : 1.61 (-0.62%)
IONS : 56.17 (+4.11%)
EXEL : 21.80 (+3.91%)
GILD : 68.14 (+0.62%)
BIIB : 322.61 (+0.88%)
The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen

IBB : 105.48 (+1.26%)
GILD : 68.14 (+0.62%)
REGN : 377.96 (+0.60%)
ALXN : 117.01 (+1.90%)
BIIB : 322.61 (+0.88%)
4 Biotech Stocks Investors Can Add to Their Portfolio in 2019

Year 2018 so far has been tough for the biotech sector. Let us take a look at four stocks that can be compelling choices for 2019.

GILD : 68.14 (+0.62%)
REGN : 377.96 (+0.60%)
BIIB : 322.61 (+0.88%)
ALXN : 117.01 (+1.90%)
Biogen (BIIB) In-Licenses ALS Candidate BIIB067 From Ionis

Biogen (BIIB) obtains a license to develop and commercialize BIIB067 from Ionis Pharmaceuticals. The candidate is being developed for treatment of ALS with SOD1 mutations.

IONS : 56.17 (+4.11%)
GILD : 68.14 (+0.62%)
BIIB : 322.61 (+0.88%)
ALXN : 117.01 (+1.90%)
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data

- Positive interim analysis demonstrated proof-of-biology and proof-of-concept for BIIB067

IONS : 56.17 (+4.11%)
BIIB : 322.61 (+0.88%)
FDA Accepts BLA & Gives Priority Review to Novartis' AVXS-101

The FDA accepts Novartis' (NVS) BLA for AVXS-101 and grants Priority Review to the same.

QURE : 29.56 (+2.89%)
AXON : 1.21 (-2.42%)
NVS : 88.13 (+1.04%)
BIIB : 322.61 (+0.88%)
AbbVie Presents Long-Term Data on Cancer Drugs at ASH 2018

AbbVie (ABBV) presents positive long-term data from two separate clinical studies evaluating its cancer drugs, Venclexta and Imbruvica, in leukemia patients at the American Society of Hematology (ASH)...

ABBV : 88.60 (+0.49%)
TEVA : 18.99 (+2.59%)
RHHBY : 32.2600 (+2.09%)
BIIB : 322.61 (+0.88%)
Teva's Rituxan Biosimilar Gets FDA Nod in Non-Hodgkin Lymphoma

Teva (TEVA) and partner Celltrion get FDA nod for approval of their biosimilar to Roche's Rituxan in three Non-Hodgkin's lymphoma indications.

NVS : 88.13 (+1.04%)
TEVA : 18.99 (+2.59%)
RHHBY : 32.2600 (+2.09%)
BIIB : 322.61 (+0.88%)
International Prix Galien Recognizes SPINRAZA(R) as Best Biotechnology Product

Rare disease therapy honored with seven Prix Galien awards, including six independent country recognitions, for innovation in treating spinal muscular atrophy

IONS : 56.17 (+4.11%)
BIIB : 322.61 (+0.88%)
Biogen Becomes #34 Most Shorted Nasdaq 100 Component, Replacing Liberty Global

The most recent short interest data has been released for the 11/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the...

BIIB : 322.61 (+0.88%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 335.51
1st Resistance Point 329.06
Last Price 322.61
1st Support Level 317.85
2nd Support Level 313.09

See More

52-Week High 388.67
Fibonacci 61.8% 335.38
Last Price 322.61
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar